Claris Lifesciences has received USFDA approval for generic Tobramycin injection used for the treatment of bacterial infections. The estimated market size of the product in the US is $6 million. With this approval, the company has a total of 14 approvals and 24 under approval ANDAs and is expecting more product approvals during the year
Company Profile : Claris Lifesciences Ltd
Leave a Reply